32nd European Congress of Clinical Microbiology & Infectious Diseases, took place for the first time as a hybrid event both online and on-site in Lisbon, Portugal on 23 - 26 April 2022.
ECCMID, as the world’s premier Clinical Microbiology & Infectious Diseases event, brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues. This year, the congress will feature a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted programme.
Monday, April 25, 2022
Roche integrated symposium
Current and Future Impact of COVID-19 Diagnostics on Patient Management
Joseph Yao, MD, Mayo Clinic, Rochester, United States
Optimizing Patient Workflow in the Hospital with Testing at the Point of Care
Martin Möckel, MD, Charité -Universitätsmedizin Berlin, Germany
Testing patients for clinical chemical variables and blood gases at the point of care (POC) is international standard, as it is assumed that urgently needed decisions are supported. New developments of POC PCR instruments allow additional parameters like virus diagnostics. With the COVID-19 pandemic, rapid virus diagnostics became much more important than ever before. While antigen testing became easily available, it lacks sensitivity and was insufficient in many hospital settings. Thus, POC PCR of SARS-CoV-2 makes the difference for the acute hospital setting.
Mitigating the Impact of the Pandemic on Testing Services - Business as Usual in the Laboratory?
Mark Hopkins, PhD, Liverpool University Hospitals NHS Trust, United Kingdom
Pandemic response from the perspective of a UK laboratory with a particular focus on test demand and laboratory adaptations. Some insight to how we adapted to meet the challenges of SARS-Cov-2 in conjunction with clinical teams and national procurement policy.
Joseph Yao
MD
Mayo Clinic
Rochester, United States
Dr. Yao is currently the director of the Viral Hepatitis / HIV / COVID Testing Laboratory at the Mayo Clinic and Mayo Clinic Laboratories in Rochester, Minnesota, U.S.A. and an associate professor of medicine and laboratory medicine and pathology at the Mayo Clinic College of Medicine and Science. He is a graduate of University of Manitoba, Canada, and received postgraduate medical training in internal medicine, infectious diseases, and medical microbiology at the Mayo Clinic, Harvard Medical School, and University of Toronto. He currently serves as the vice-chair of the CLSI document development committee for the 2 nd edition of M53-A Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection. His research interests are in transplant infectious diseases and the development of serologic and molecular diagnostic assays for hepatitis viruses and HIV.
Martin Möckel
MD
Charité – Universitätsmedizin Berlin
Berlin, Germany
Martin Möckel is a Senior Physician, Professor of Cardiology and Head of Emergency Medicine and Acute Cardiovascular Care at Charité-Universitätsmedizin Berlin, Germany. His research focuses on biomarkers and the application of interventional therapy in acute coronary care and acute heart failure. He has led a number of multicentre trials and recently engaed in digital health and health care research. He is an Adjunct Professor at the James Cook University, School of Public Health and Epidemiology, Townsville, Australia. Professor Möckel is joint Head of the electronic and mHealth group, part of the German Cardiac Society. Professor Möckel has delivered more than 200 oral and poster presentations at leading national and international conferences and has published extensively in the fields of emergency medicine and acute cardiac care. He is part of the biomarker core groups of the Acute Cardiovascular Care Association.
Mark Hopkins
PhD
Liverpool University Hospitals NHS Trust
Liverpool, United Kingdom
Mark is a Consultant Clinical Scientist in Infection & Immunity at Liverpool Clinical Laboratories. After completing a PhD in molecular microbiology at the University of Cambridge and a post-doc position investigating 16S rRNA profiles Mark trained as a Clinical Scientist at the Specialist Virology Centres in Edinburgh and Liverpool. Subsequently he attained fellowship with the Royal College of Pathologists and took a consultant position at Barts Health, London. Mark returned to Liverpool as a Consultant Virologist in December 2020. He is also a Virologist for the NHS Cervical Screening Programme and is an Honorary Senior Clinical Lecturer in Molecular Diagnostics and Therapeutics at Barts Cancer Institute, Queen Mary University of London.
